A Global Leader in
Molecular Glue Degrader-Based Drug Discovery
GluBio Therapeutics, Inc. is a biotech company dedicated to the discovery and development of innovative molecular glue degraders (MGDs). Founded in March 2021, GluBio operates R&D centers in Zhangjiang Science City, Shanghai, and San Diego, California.
As a global leader in molecular glue degrader biotechnology, GluBio is powered by an experienced international leadership team in molecular glue R&D. The company has built a highly efficient, proprietary molecular glue discovery platform and is advancing molecular glue therapeutics across multiple disease areas, including oncology, autoimmune disorders, and genetic diseases, to address unmet clinical needs.
Pipeline
Focused on discovering and developing ‘First-in-class’ and ‘Best-in-class’ molecular glue–based protein degradation therapies.
IKZF 1/3Latest News
-
December 10, 2025GluBio Announced Positive Preliminary Phase I Results for GLB-002 at the 2025 ASH Annual MeetingLearn More
-
February 27, 2024Successful Completion of Dose Escalation at the First Dose Level in the Ongoing Phase 1 Trial of GLB-002 in Patients with R/R NHLLearn More
-
February 20, 2024GLB-001, China’s First Selective CK1α Molecular Glue Protein Degrader, Approved for Clinical TrialsLearn More